HepaRegeniX

CompanyGermany

HepaRegeniX develops one asset, in human trials (darizmetinib in post-hepatectomy liver failure). Mostly small molecule acting on MAP2K4; based in Germany.

1
Asset
Furthest stage: Human trials; 0
Trials: 1
Signal

Pipeline

1

darizmetinib
Inhibits MKK4 to promote hepatocyte proliferation and liver regeneration.
Human trials, Small molecule, MAP2K4, post-hepatectomy liver failure

Full company profiles: pipeline, trials, funding and people.

In the full profile

Evidence behind the mechanisms1
Signals1